An Amgen (AMGN) employee violated Danish law by sharing and liking a U.S. press release about a medicine on LinkedIn, but will not be sanctioned, nor is the company being held responsible for the incident, the Danish Medicines Agency has decided. The employee could have faced up to four months in jail and the drug maker might have been liable for a penalty.

The press release in question was issued last August and contained positive study results about the Kyprolis cancer treatment when compared with another medicine called Velcade. And the results indicated that Kyprolis should replace Velcade as the standard of care when a patient relapses with multiple myeloma.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy